News

Explore the top headlines of the week including insights on voluntary recalls, DIMIDs and pandemic risks, and AAD pearls.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about positive results from Incyte’s phase 3 STOP-HS trials, multidisciplinary approaches to advanced BCC and CSCC, pediatric ocular adverse effects associated with dupilumab, and more.

This week, we feature top articles from our sister publications on long COVID recovery, integrating AI into pharmacy, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Eve Arnera and Thandiwe Munaiwa, MD, spoke about the groundbreaking collaboration between SkinCeuticals and ReSurge International, “Pioneering Women in Reconstructive Surgery.”

At week 24, the proportion of Asian patients achieving significant hair regrowth (SALT ≤20) was substantially higher in ritlecitinib treatment groups than in placebo groups.

Participants reported increased confidence in clinical interactions and greater interest in dermatology as a career path.

In part 2 of this Frontline Forum supplement, experts discuss current and emerging treatments, digital tools and supports, and more.

The 730-nm picosecond laser had an efficacy rate of 88% with higher patient satisfaction compared to the 1604-nm wavelength.

Estrogen therapy and certain diuretics may increase skin cancer risk, highlighting the need for careful patient counseling and sun exposure management.

Key estate planning changes in 2025: potential tax law shifts, federal exemption sunset, retirement account rules, state death taxes, and cryptocurrency issues.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The review also found that female patients with non melanoma skin cancer demonstrated a greater risk of completed suicide compared to members of a control group.

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.

This real-world data explores the use of the IL-17A blocker for up to 3 years in several subtypes of psoriasis.

A recent study highlights the need for ophthalmologic monitoring in pediatric dupilumab therapy.

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.

A 30-year-old patient with dermatofibrosarcoma protuberans faced a recurrence after initial surgery. Mohs micrographic surgery was used for precise excision, reducing recurrence risk and improving outcomes.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.

Participants experienced smoother, younger-looking skin after just 1 session, with results lasting up to 16 weeks.

The investigational drug, designed using AI technology, optimizes pharmacologic characteristics for psoriasis treatment.

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

Valerie Harvey, MD, MPH, FAAD, discusses pigmentary disorders like melasma and hyperpigmentation, highlighting their disproportionate impact on women, particularly those with skin of color.

This review of the latest dermatologic studies includes insights into supporting laser tattoo removal for adults impacted by the justice-system, a case of blastic plasmacytoid dendritic cell neoplasm, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

In part 1 of this Frontline Forum supplement, experts discuss the burden of HS, reducing diagnostic delays, and more.